Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. (4th March 2017)

• Record Type: Journal Article
• Authors: Marcellin, Fabienne; Roux, Perrine; Protopopescu, Camelia; Duracinsky, Martin; Spire, Bruno; Carrieri, Maria Patrizia
• Is Part Of: Expert review of gastroenterology & hepatology. Volume 11:Number 3(2017)
• Page Start: 259
• Page End: 268
• Publication Date: 2017-03-04
• Subjects: Chronic infection -- direct-acting antivirals -- drug users -- fatigue -- hepatitis C -- key populations -- patient-reported outcomes -- risk behaviors -- quality of life -- reinfection; Gastroenterology -- Periodicals; Liver -- Diseases -- Periodicals; 616.3
• DOI: 10.1080/17474124.2017.1285227
• Languages: English
• ISSNs: 1747-4124

Abstract

ABSTRACT: Introduction : Patient-reported outcomes (PROs) play a key role in the evaluation of direct-acting antivirals (DAA) for the treatment of chronic hepatitis C (CHC). The main PROs of particular interest in CHC include quality of life (QoL), fatigue and its functional repercussions, work productivity, adherence to treatment, and risk behaviors. Areas covered : This study summarizes the body of knowledge regarding PROs in CHC with DAA-based therapy. Outstanding related issues are presented and discussed. Expert commentary : Current knowledge on PROs with CHC mainly relies on clinical trial data. All-oral DAA regimens are associated with minimal QoL impairment and symptom burden, rapid recovery once treatment has ended, and improvement in PROs for a non-negligible proportion of treated patients, especially HCV clearers. Further research is needed to analyze both long-term changes in PROs, and PROs in specific populations including people who use drugs, comorbid patients and patients at risk of reinfection.